Compare Crispr Therapeutics AG (CRSP) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ishares Msci Thailand Etf — how do they compare? Crispr Therapeutics AG trades at $50.63 (market cap $4.97B), while Ishares Msci Thailand Etf trades at $72.74. The key difference: Ishares Msci Thailand Etf is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | THD | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $75.05 |
52-Week Low | $44.34 | $53.63 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
THD trades at $72.33, down 0.25% on the day, with technical indicators showing a bullish trend from moving averages and neutral oscillators. The stock faces key support at $72 and resistance at $73. A dividend of $1.71 is scheduled for payment on June 18, 2026. Recent news highlights THD's strong performance as an ASEAN ETF, driven by exposure to Delta Electronics and AI hardware plays, though this concentration introduces vulnerability to profit-taking.
The outlook for THD is cautiously optimistic given its technical strength and thematic tailwinds from AI, but risks include over-reliance on single holdings and regional economic sensitivity. Investors should weigh the ETF's recent outperformance against potential volatility from geopolitical and monetary policy shifts affecting Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
